To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Effective oral combinatio… - University of Gothenburg, Sweden Till startsida
Sitemap
To content Read more about how we use cookies on gu.se

Effective oral combination metronomic chemotherapy with low toxicity for the management of castration-resistant prostate cancer.

Journal article
Authors Åsa Jellvert
Ingela Frank-Lissbrant
Maliha Edgren
Elisabeth Ovferholm
Karin Braide
Ann-Marie Ekelund Olvenmark
Jon Kindblom
Per Albertsson
Bo Lennernäs
Published in Experimental and therapeutic medicine
Volume 2
Issue 4
Pages 579-584
ISSN 1792-1015
Publication year 2011
Published at Institute of Clinical Sciences, Department of Oncology
Pages 579-584
Language en
Links dx.doi.org/10.3892/etm.2011.272
Subject categories Clinical Medicine, Cancer and Oncology

Abstract

Prostate cancer (PC) was previously believed to be a chemoresistant disease. In recent years taxane-based chemotherapy has been shown to prolong survival in patients with castration-resistant prostate cancer (CRPC). It remains to be shown, however, which type of chemotherapy provides the most beneficial effect with the least amount of side effects. Seventeen patients with chemonaive CRPC were enrolled in a pilot study evaluating an orally administered chemo-hormonal treatment regimen using a weekly sequential combination called KEES; consisting of ketoconazole in combination with cyclophosphamide or etoposide in combination with estramustine administered on alternate weeks. Prednisone was administered throughout the treatment period. Prostate-specific antigen (PSA) response and acute and chronic toxicities were evaluated. Seventeen patients with CRPC were treated; eleven patients demonstrated a median reduction in PSA of 87% (range 26-99%). Ten (59%) patients responded with a decrease in PSA >50%. Thrombocytopenia and anaemia were the most common side effects. One study fatality was reported, however, it was unclear whether this was treatment related. In conclusion, KEES may be a promising option for patients with CRPC, resulting in a clear reduction in PSA with limited toxicity. Further clinical evaluation of this metronomic chemohormonal combination is underway.

Page Manager: Webmaster|Last update: 9/11/2012
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?